Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's. Find out why AVXL stock is a Sell.

Medpace's backlog growth remains sluggish, but a healthy book-to-bill ratio and potential sector recovery could accelerate ...